Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2025 05:00 ET | Source: AiCuris Anti-infective Cures AG

Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy...
October 16, 2025 05:00 ET | Source: AiCuris Anti-infective Cures AG

Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments...
September 16, 2025 05:00 ET | Source: AiCuris Anti-infective Cures AG

Aicuris Announces Upcoming Oral and Poster Presentations at ID Week 2025

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overviewUpdated safety and pharmacokinetic results of...
August 05, 2025 05:00 ET | Source: AiCuris Anti-infective Cures AG

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK)...
July 24, 2025 05:00 ET | Source: AiCuris Anti-infective Cures AG

Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients

Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment...
September 24, 2024 11:09 ET | Source: Tevogen Bio Inc

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
September 19, 2023 09:00 ET | Source: GeoVax, Inc.

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
March 28, 2022 09:00 ET | Source: Physicians for Informed Consent

Physicians for Informed Consent Updates Its Information Statement About Vaccines and Immunocompromised Schoolchildren, Includes Data on COVID-19 Vaccines

NEWPORT BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent (PIC), an educational nonprofit organization focused on science and statistics, has released an update to...
February 02, 2022 10:49 ET | Source: American College of Rheumatology

Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients

Atlanta, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and...
March 03, 2015 14:41 ET | Source: Weston A. Price Foundation

Public Health Officials Know: Recently Vaccinated Individuals Spread Disease

Washington, D.C., March 3, 2015 (GLOBE NEWSWIRE) -- Physicians and public health officials know that recently vaccinated individuals can spread disease and that contact with the immunocompromised can...